Can ancient chinese movement training help scarred lungs work harder?
NCT ID NCT07019714
First seen Sep 29, 2026 · Last updated Sep 30, 2026 · Updated 1 time
Summary
Researchers are testing whether Daoyin, a traditional Chinese practice combining gentle movement and breathing exercises, can improve exercise endurance in adults with idiopathic pulmonary fibrosis. The trial enrolls 236 people aged 40 to 85 who can tolerate the training, including some who use a smartphone or computer for home sessions. Participants receive Daoyin alongside standard guideline-based care, and researchers measure changes in a six-minute walk distance and a 30-second sit-to-stand test, plus how often flare-ups occur.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Daoyin Technique, a traditional Chinese mind-body movement and breathing practice
- What this could lead to
- If it helps, this could give people with idiopathic pulmonary fibrosis a low-cost, home-based way to stay active and breathe more easily alongside standard care.
- What could go wrong
- Exercise training does not reverse lung scarring, so any benefit would likely be modest and limited to fitness and daily function. Participants must be stable enough to train, and results may not apply to those with more advanced disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 236 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2026
- Expected to finish
-
Nov 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients who meet the diagnostic criteria for IPF; 2. Those who can tolerate guided - technique training; 3. Aged between 40 and 85 years old; 4. Those who can independently or with the assistance of family members use devices such as smartphones and computers during home - based training; 5. Those who voluntarily accept treatment and sign the informed consent form. Exclusion Criteria: 1. Patients in the acute exacerbation phase of IPF. 2. Patients with comorbidities such as chronic obstructive pulmonary disease, lung cancer, active pulmonary tuberculosis, bronchiectasis, pulmonary embolism, and other pulmonary diseases. 3. Patients with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, cardiac function at grade 3 or above, stroke, cerebral hemorrhage, etc.). 4. Patients with severe liver diseases (such as bleeding caused by liver cirrhosis, portal hypertension, and esophagogastric varices) and severe kidney diseases (dialysis, kidney transplantation, etc.). 5. Patients with severe osteoarthropathy or osteoporosis, and those with unstable fractures. 6. Patients with progressive neuromuscular diseases. 7. Patients with unclear consciousness, dementia, and various mental illnesses. 8. Pregnant or lactating women, and patients with a recent pregnancy plan. 9. Patients who have been participating in other clinical trials within 1 month before enrollment. 10. Patients who need long - term use of ventilators and those with unstable vital signs while bedridden.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Idiopathic pulmonary fibrosis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The Affiliated Hospital of Liaoning University of Traditional Chinese Medicinenese Medicine
RECRUITINGShenyang, Liaoning, China
-
The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
RECRUITINGZhengzhou, Henan, 450000, China
-
Xiyuan Hospital of China Academy of Chinese Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100091, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- PET scan lights up lung scarring to guide treatment
- Can an inhaled drug slow scarring in deadly lung disease?
- Inhaled drug candidate tested for deadly lung scarring
- Opioid-Based pill tested against the relentless cough of lung fibrosis
- New peptide drug targets lung scarring in IPF
- Patients and families build a living database of pulmonary fibrosis